Certara (NASDAQ:CERT) Price Target Cut to $14.00 by Analysts at Barclays

Certara (NASDAQ:CERTGet Free Report) had its target price reduced by equities researchers at Barclays from $16.00 to $14.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Barclays‘s price objective would indicate a potential upside of 24.22% from the company’s previous close.

Several other research firms have also commented on CERT. KeyCorp dropped their price target on Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Robert W. Baird dropped their price objective on shares of Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, September 27th. Finally, JMP Securities reissued a “market perform” rating on shares of Certara in a report on Wednesday, July 10th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $17.08.

Check Out Our Latest Research Report on Certara

Certara Stock Performance

NASDAQ:CERT traded up $0.03 during trading hours on Tuesday, reaching $11.27. 502,687 shares of the stock were exchanged, compared to its average volume of 745,187. The stock has a market capitalization of $1.81 billion, a P/E ratio of -28.90, a P/E/G ratio of 5.40 and a beta of 1.49. The firm has a 50 day simple moving average of $11.78 and a 200-day simple moving average of $14.55. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28. Certara has a 52 week low of $10.35 and a 52 week high of $19.87.

Certara (NASDAQ:CERTGet Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The business had revenue of $93.31 million during the quarter, compared to analyst estimates of $96.01 million. During the same period in the prior year, the firm earned $0.10 EPS. The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Certara will post 0.27 earnings per share for the current fiscal year.

Insider Transactions at Certara

In related news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the sale, the insider now owns 99,704 shares in the company, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.39% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Certara

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wasatch Advisors LP boosted its stake in shares of Certara by 23.4% during the 1st quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock worth $88,056,000 after acquiring an additional 932,598 shares during the period. Geneva Capital Management LLC boosted its holdings in shares of Certara by 15.1% during the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock worth $78,747,000 after buying an additional 579,349 shares during the period. Clearbridge Investments LLC raised its holdings in Certara by 0.8% in the 1st quarter. Clearbridge Investments LLC now owns 4,173,195 shares of the company’s stock valued at $74,617,000 after acquiring an additional 32,846 shares during the period. Dimensional Fund Advisors LP lifted its position in Certara by 9.7% during the second quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock worth $42,643,000 after acquiring an additional 273,095 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Certara by 9.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,773,892 shares of the company’s stock worth $38,418,000 after acquiring an additional 248,448 shares during the period. 73.96% of the stock is owned by institutional investors.

Certara Company Profile

(Get Free Report)

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

Featured Articles

Analyst Recommendations for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.